A natural PCID2-Targeting compound suppresses hepatocellular carcinoma progression: evidence from structure-based discovery and biological evaluation
β-PGG exhibits potent anti-HCC activity by modulating PCID2 expression, PI3K/Akt signaling, and cell cycle regulation, and it represents a promising lead compound with PCID2-targeting potential. This study not only support a rationale for further exploration of PCID2 as a therapeutic target in HCC but also provide valuable insights into the discovery of novel lead compounds from TCM for liver cancer treatment.
Authors
- Jia-Ping Huang
- Jiamin Song (ORCID: https://orcid.org/0000-0001-9815-8508)
- Huiyu Zhang (ORCID: https://orcid.org/0000-0002-1354-1581)
- Lili Xi (ORCID: https://orcid.org/0000-0001-5664-5850)
- Jingjing Sun (ORCID: https://orcid.org/0009-0009-2397-4469)
- Jingjing Guo
- Xinyi Luo (ORCID: https://orcid.org/0000-0002-6292-7376)
- Zebanuer Yuemaierjiang
Institutions
- First Hospital of Lanzhou University (CN)
- Macao Polytechnic University (MO)
- Lanzhou University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-28
- DOI
- https://doi.org/10.3389/fphar.2025.1687517
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Lanzhou University